Mycophenolate Mofetil Monotherapy in Patients Who Underwent Liver Transplantation for Hepatitis C Cirrhosis

Transplantation Proceedings

Volumn 40, Issue 9, 2008, Pages 2962-2964

  Manrique, A ^a   Jimenez C ^a   Ortega, P ^a   Abradelo, M ^a   Gimeno, A ^a   Calvo, J ^a   Cambra, F ^a   Sterup, R L ^a   Morales, J M ^a   Moreno, E ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ABDOMINAL DISCOMFORT; ACUTE GRAFT REJECTION; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEPATITIS C; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROTOXICITY; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; THROMBOCYTOPENIA; VOMITING;

ADULT; CALCINEURIN; CREATININE; FEMALE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 55749096558     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.09.040     Document Type: Article

References (17)

1. Mason J. Pharmacology of cyclosporine (Sandimmune). VII. Pathophysiology and toxicology of cyclosporine in human and animals. Pharmacol Rev 41 (1990) 423
2. Spencer C.M., Goa K.L., and Gillis J.C. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54 (1997) 925
3. Patterson J.L., and Fernández-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 12 (1990) 1139
4. Peters D.H., Fitton A., Plosker G.L., et al. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46 (1993) 764
5. Mouraud G., Vela C., Ribstein J., et al. Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy. Transplantation 65 (1998) 661
6. Herrero J.I., Quiroga J., Sangro B., et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 5 (1999) 414
7. Barkmann A., Nashan B., Schmidt H.H.J., et al. Improvement of acute and chronic renal dysfunction in liver transplant recipients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 69 (2000) 1886
8. Raimondo M.L., Dagher L., Papatheodoridis G.V., et al. Long-term mycophenolate mofetil in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 75 (2003) 186
9. Koch R.O., Graziadei I.W., Schulz F., et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 17 (2004) 518
10. Papatheodoridis G.V., O'Beirne J., Mistry P., et al. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment. A preliminary report. Transplantation 68 (1999) 155
11. Schlitt H.J., Barkmann A., Boker A., et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver transplant patients with renal dysfunction: a randomized controlled study. Lancet 357 (2001) 609
12. Stewart S.F., Hudson M., Talbot D., et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 357 (2001) 609
13. Moreno J.M., Cuervas-Mons V., Rubio E., et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 4 (2004) 1650
14. Fairbanks K.D., and Thuluvath P.J. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 10 (2004) 1189
15. Orlando G., Baiocchi L., Cardillo A., et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension. Liver Transpl 13 (2007) 46
16. Smallwood G.A., Davis L., Martńez E., et al. Mycophenolate's influence in the treatment of recurrent hepatitis C following liver transplantation. Transplant Proc 34 (2002) 1559
17. Fasola C.G., Netto G.J., Jennings L.W., et al. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplant Proc 34 (2002) 1563